Gene therapy for mesothelioma and lung cancer.
Both malignant pleural mesothelioma and advanced stage lung cancer are associated with a poor prognosis. Unfortunately, current treatment regimens have had only a modest effect on their progressive course. Gene therapy for thoracic malignancies represents a novel therapeutic approach and has been evaluated in a number of clinical trials over the last two decades. Using viral vectors or anti-sense RNA, strategies have included induction of apoptosis, tumor suppressor gene replacement, suicide gene expression, cytokine-based therapy, various vaccination approaches, and adoptive transfer of modified immune cells. This review will consider the clinical results, limitations, and future directions of gene therapy trials for thoracic malignancies.
University of Pennsylvania, 1016B Abramson Research Center, 3615 Civic Center Blvd., Philadelphia, PA 19104-6160, USA.
Anil
A
Vachani
Edmund
E
Moon
Elliot
E
Wakeam
Steven M
SM
Albelda
D019264:Adoptive Transfer / Q000379:methods; D000818:Animals; D017209:Apoptosis / Q000235:genetics / Q000276:immunology; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000235:genetics / Q000276:immunology; D041722:Genes, Transgenic, Suicide / Q000235:genetics / Q000276:immunology; D016147:Genes, Tumor Suppressor; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D008654:Mesothelioma / Q000175:diagnosis / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D010997:Pleural Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D011379:Prognosis; D016372:RNA, Antisense / Q000235:genetics / Q000276:immunology; D014780:Viruses / Q000235:genetics
D019496:Cancer Vaccines; D016207:Cytokines; D016372:RNA, Antisense